iNtODEWORLD | Our research is committed to finding effective treatment for life-threatening infectious diseases.
15234
home,page,page-id-15234,page-template,page-template-full_width,page-template-full_width-php,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

iNtODEWORLD

A Game Changer in Antibacterial Drugs for Superbugs and Persister Cells

We are committed to finding effective treatment for life-threatening infectious diseases.

maintopban1

A Game Changer in Antibacterials Treatment for Gram-negative bacteria, Ultimate Target of N-Rephasin® Technology

maintopban2

Eco-friendly, no Side-effects, Unique mode of action. Bacteriophages and Antibiotic Resistance in Bacteria

maintopban3

Opening a New Era in Anti-Fugal Agents. A New Type of Antifungal Agent, iN-EYD34

maintopban4

New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent

iNtRON Biotechnology, Inc.

iNtRON Bio has been focusing on the R&D investment since its foundation and accelerates development speed after the IPO in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.

INSIDE iNtRON

  • iNtRON Biotechnology has announced that N-Rephasin BAL200 for the treatment of anthrax infection has been received Orphan Drug Designation (ODD) from the US Food and Drug Administration (US FDA). Orphan Drug Designation is a program of FDA to support for the new drug development of rare......

  • On June 22, 2018, The 6th Korea Bacteriophage Research Society meeting was held at the iNtRON Bio’s conference room. 40 prominent bacteriophage researchers and related industry specialists have  participated in the meeting, and Professor Yong of Yonsei University, Professor Bae of Seoul National University, and Research......

  • To Focus on Investor Relations and Global Business Development As iNtRON Biotechnology (hereafter “iNtRON”) has grown up steadily, iNtRON has opened a new Seoul Office in the center of Seoul with great accessibility to focus on global business and investor relations. iNtRON is developing novel......

See All
seh

PIPELINES

iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.

iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.
PGlmcmFtZSB3aWR0aD0iNzAwIiBoZWlnaHQ9IjM5NCIgc3JjPSJodHRwczovL3d3dy55b3V0dWJlLmNvbS9lbWJlZC81UDMxdTh6emF6az9yZWw9MCIgZnJhbWVib3JkZXI9IjAiIGFsbG93PSJhdXRvcGxheTsgZW5jcnlwdGVkLW1lZGlhIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+